Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutical company focused on reducing cisplatin-induced ototoxicity in cancer patients through its therapy PEDMARK®. The FENC news feed on Stock Titan aggregates company announcements, clinical updates, capital markets activity and regulatory developments that shape the outlook for this ototoxicity-focused business.
Investors and healthcare observers can review news about regulatory and commercial milestones for PEDMARK® in the United States and PEDMARQSI® in Europe and the U.K., as well as licensing developments with Norgine Pharmaceuticals Ltd. Updates on investigator-initiated and investigator-sponsored trials, including studies in Japan and at institutions such as City of Hope, provide insight into how PEDMARK® is being evaluated across different tumor types, age groups and geographies.
The Fennec news stream also covers financing transactions and balance sheet actions, such as underwritten public offerings of common shares, non-brokered offerings in Canada, and the use of proceeds to repurchase and redeem senior secured floating rate convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP. These items help investors understand how the company funds commercialization and clinical collaborations while managing its capital structure.
Additional releases may highlight participation in healthcare conferences, changes in institutional shareholdings, and other corporate communications. By following this page, readers can access an organized view of Fennec’s official disclosures, from clinical data readouts and commercialization updates to securities offerings and debt redemptions, all in one place.
Fennec Pharmaceuticals (NASDAQ:FENC) announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On March 31, 2026 the company granted incentive stock options to 24 new non-executive employees covering 377,500 shares under its 2026 Equity Inducement Plan.
All ISOs carry an exercise price of $5.77 (closing price on March 30, 2026), a 10-year term, and vest one-third after one year then monthly over the next 24 months, subject to continued employment.
Fennec Pharmaceuticals (NASDAQ: FENC) reported FY2025 net product sales of $44.6M (up 50% YoY) and Q4 2025 net product sales of $13.8M (up 75% YoY). Cash was $36.8M at year-end after oversubscribed $42M equity offerings and a $21.5M debt paydown, leaving $0 debt outstanding. The company reported a FY2025 net loss of $10.1M and continues to expand PEDMARK adoption, investigator-led studies, and real-world data generation.
Fennec Pharmaceuticals (NASDAQ: FENC) will release full year and fourth quarter 2025 financial results before U.S. markets open on March 24, 2026.
Management will host an 8:30 a.m. ET conference call and webcast the same day; a replay will be archived on the company website for 30 days.
Fennec Pharmaceuticals (NASDAQ:FENC) announced a settlement with Cipla resolving PEDMARK patent litigation. The lawsuit will be dismissed and Cipla agrees not to market a generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under certain circumstances. PEDMARK is FDA‑approved to reduce cisplatin‑related ototoxicity in pediatric patients ≥1 month; pivotal Phase 3 data and safety rates are summarized in prescribing information.
Fennec Pharmaceuticals (NASDAQ:FENC) announced a clinical research collaboration with Tampa General Hospital Cancer Institute to evaluate real-world use of sodium thiosulfate injection (PEDMARK®) for reducing cisplatin-related ototoxicity in adolescent, young adult (AYA) and adult patients with non-metastatic solid tumors.
The study will analyze clinical and audiology monitoring data; PEDMARK is approved for pediatric patients aged one month and older and has a NCCN 2A recommendation for AYA patients.
Fennec Pharmaceuticals (NASDAQ:FENC) presented multi-institutional real-world data on PEDMARK® for adults with head & neck cancers at MHNCS, Feb 19–21, 2026. A retrospective review of 15 adults found PEDMARK® given ≥6 hours after cisplatin was safely integrated into care with no disruption to curative-intent cisplatin delivery.
Most high-risk patients showed no measurable hearing loss during or after treatment, PEDMARK® had only isolated, self-limited infusion events and no grade 3–4 toxicities, supporting further exploration in head & neck cancer populations.
Southpoint Capital Advisors LP announced that on Dec 24, 2025 it disposed of beneficial ownership of 1,000,000 common shares of Fennec Pharmaceuticals (TSX: FENC), representing approximately 2.93% of outstanding common shares on a fully diluted basis. The Common Shares were sold at USD $7.50 per share. After the disposition, Southpoint reports it now controls or directs 2.7 million common shares, representing about 8% of outstanding shares on a fully diluted basis. Southpoint said the shares were disposed for investment purposes and that it may change its ownership or control through market transactions, private agreements, treasury issuances, or exercise of warrants.
Fennec Pharmaceuticals (NASDAQ:FENC) announced that City of Hope will initiate an investigator‑sponsored Phase I study (NCT07218913) to evaluate PEDMARK® (sodium thiosulfate) for prevention of cisplatin‑induced ototoxicity in adult men with stage II‑III metastatic testicular germ cell tumors on Dec 9, 2025. The study tests adding PEDMARK to standard cisplatin chemotherapy to reduce permanent hearing loss. PEDMARK is approved for pediatric localized non‑metastatic solid tumors and has a NCCN 2A recommendation for adolescent and young adult patients. Multiple other investigator‑initiated studies are under review or contracting, with additional details to be shared as programs progress.
Fennec Pharmaceuticals (NASDAQ: FENC) reported positive topline results from the investigator‑initiated Phase 2/3 STS-J01 study of PEDMARK® in Japan to reduce cisplatin‑induced hearing loss in pediatric and AYA patients.
The primary cohort (n=27, ages 3–18) met its endpoint: hearing loss rates were 24% (ASHA) and 16% (Brock) with PEDMARK®, versus historically reported cisplatin‑only rates of 56% (ASHA) and 63% (Brock). Pharmacokinetics showed no reduction in cisplatin exposure and tumor response rate was approximately 95%. PEDMARK® was well tolerated; no adverse events were attributed to the drug. Fennec plans to pursue registration in Japan and explore partnering or licensing opportunities.
Fennec Pharmaceuticals (NASDAQ: FENC) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET. The session will be available via live webcast and an archived replay will be posted after the event.
Investors can access the live webcast via the provided webcast link or from the Events page in the Investors section of the company website (www.fennecpharma.com).